Logotipo de HISPANA
Logotipo del Ministerio de Cultura y Deporte
  • Zer da HISPANA?
  • Bilaketa
  • Bildumen direktorioa
  • Harremanetarako
  • eu
    • Español
    • Euskara
    • English
    • Galego
    • Català
    • Valencià
Está en:  › Erregistro
Linked Open Data
A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)
Identificadores del recurso
Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.
1664-0640
http://hdl.handle.net/20.500.13003/9541
10.3389/fpsyt.2017.00258
29326609
L619582782
2-s2.0-85037623572
000416792100001
Jatorria
(Docusalut. Repositorio institucional del sistema sanitario público de las Islas Baleares)

Fitxa

Izenburu:
A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)
Tema:
platelet biomarker
IRAS/nischarin
cocaine use disorder
major depressive disorder
cocaine-induced depression
acute tryptophan depletion
antidepressant drugs
Deskribapen:
The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.
The study was supported by grants SAF2011-29918 (JAG-S) and SAF2014-55903-R (MJG-F) from Ministerio de Economia y Competitividad (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) and by grants PS09/02121 and PI12/01838 (MT) from Instituto de Salud Carlos III (ISCIII) and FIS-FEDER, Madrid, Spain. The research was also funded by Redes Tematicas de Investigacion Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011, RD12/0028/0009, RD16/0017/0003, and RD16/0017/0010) (ISCIII and FEDER), Madrid, Spain. This work was also supported by grants 2012/011 and 2016/002 (MJG-F) from Delegacion del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain. BK was supported by a predoctoral contract from RETICS-RTA. MJG-F is a Ramon y Cajal Researcher (MINECO-UIB). JG-S is a member of the Institut d'Estudis Catalans (Barcelona, Catalonia, Spain). We are grateful to Esther Menoyo, Marta Perez, Soraya Martin, and Clara Gibert for their valuable assistance throughout the clinical part of the study.
Idioma:
English
Harreman:
https://dx.doi.org/10.3389/fpsyt.2017.00258
Autor/Productor:
Keller, Benjamin
Mestre-Pinto, Joan-Ignasi
Alvaro-Bartolome, Maria
Martinez-Sanvisens, Diana
Farre, Magi
García-Fuster, M Julia
Garcia-Sevilla, Jesus A.
Torrens, Marta
NEURODEP Grp
Argitaratzaile:
Frontiers Media Sa
Eskubideak:
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
open access
Data:
2021-08-24T15:16:54Z
2017-12-01
Tipo de recurso:
research article

oai_dc

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">

    1. <dc:title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</dc:title>

    2. <dc:creator>Keller, Benjamin</dc:creator>

    3. <dc:creator>Mestre-Pinto, Joan-Ignasi</dc:creator>

    4. <dc:creator>Alvaro-Bartolome, Maria</dc:creator>

    5. <dc:creator>Martinez-Sanvisens, Diana</dc:creator>

    6. <dc:creator>Farre, Magi</dc:creator>

    7. <dc:creator>García-Fuster, M Julia</dc:creator>

    8. <dc:creator>Garcia-Sevilla, Jesus A.</dc:creator>

    9. <dc:creator>Torrens, Marta</dc:creator>

    10. <dc:creator>NEURODEP Grp</dc:creator>

    11. <dc:subject>platelet biomarker</dc:subject>

    12. <dc:subject>IRAS/nischarin</dc:subject>

    13. <dc:subject>cocaine use disorder</dc:subject>

    14. <dc:subject>major depressive disorder</dc:subject>

    15. <dc:subject>cocaine-induced depression</dc:subject>

    16. <dc:subject>acute tryptophan depletion</dc:subject>

    17. <dc:subject>antidepressant drugs</dc:subject>

    18. <dc:description>The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</dc:description>

    19. <dc:description>The study was supported by grants SAF2011-29918 (JAG-S) and SAF2014-55903-R (MJG-F) from Ministerio de Economia y Competitividad (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) and by grants PS09/02121 and PI12/01838 (MT) from Instituto de Salud Carlos III (ISCIII) and FIS-FEDER, Madrid, Spain. The research was also funded by Redes Tematicas de Investigacion Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011, RD12/0028/0009, RD16/0017/0003, and RD16/0017/0010) (ISCIII and FEDER), Madrid, Spain. This work was also supported by grants 2012/011 and 2016/002 (MJG-F) from Delegacion del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain. BK was supported by a predoctoral contract from RETICS-RTA. MJG-F is a Ramon y Cajal Researcher (MINECO-UIB). JG-S is a member of the Institut d'Estudis Catalans (Barcelona, Catalonia, Spain). We are grateful to Esther Menoyo, Marta Perez, Soraya Martin, and Clara Gibert for their valuable assistance throughout the clinical part of the study.</dc:description>

    20. <dc:date>2021-08-24T15:16:54Z</dc:date>

    21. <dc:date>2021-08-24T15:16:54Z</dc:date>

    22. <dc:date>2017-12-01</dc:date>

    23. <dc:type>research article</dc:type>

    24. <dc:identifier>Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</dc:identifier>

    25. <dc:identifier>1664-0640</dc:identifier>

    26. <dc:identifier>http://hdl.handle.net/20.500.13003/9541</dc:identifier>

    27. <dc:identifier>10.3389/fpsyt.2017.00258</dc:identifier>

    28. <dc:identifier>29326609</dc:identifier>

    29. <dc:identifier>L619582782</dc:identifier>

    30. <dc:identifier>2-s2.0-85037623572</dc:identifier>

    31. <dc:identifier>000416792100001</dc:identifier>

    32. <dc:language>eng</dc:language>

    33. <dc:relation>https://dx.doi.org/10.3389/fpsyt.2017.00258</dc:relation>

    34. <dc:rights>Attribution 4.0 International</dc:rights>

    35. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>

    36. <dc:rights>open access</dc:rights>

    37. <dc:publisher>Frontiers Media Sa</dc:publisher>

    </oai_dc:dc>

didl

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <d:DIDL schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">

    1. <d:DIDLInfo>

      1. <dcterms:created schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2021-08-24T15:16:54Z</dcterms:created>

      </d:DIDLInfo>

    2. <d:Item id="hdl_20.500.13003_9541">

      1. <d:Descriptor>

        1. <d:Statement mimeType="application/xml; charset=utf-8">

          1. <dii:Identifier schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:20.500.13003/9541</dii:Identifier>

          </d:Statement>

        </d:Descriptor>

      2. <d:Descriptor>

        1. <d:Statement mimeType="application/xml; charset=utf-8">

          1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">

            1. <dc:title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</dc:title>

            2. <dc:creator>Keller, Benjamin</dc:creator>

            3. <dc:creator>Mestre-Pinto, Joan-Ignasi</dc:creator>

            4. <dc:creator>Alvaro-Bartolome, Maria</dc:creator>

            5. <dc:creator>Martinez-Sanvisens, Diana</dc:creator>

            6. <dc:creator>Farre, Magi</dc:creator>

            7. <dc:creator>García-Fuster, M Julia</dc:creator>

            8. <dc:creator>Garcia-Sevilla, Jesus A.</dc:creator>

            9. <dc:creator>Torrens, Marta</dc:creator>

            10. <dc:creator>NEURODEP Grp</dc:creator>

            11. <dc:description>The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</dc:description>

            12. <dc:date>2021-08-24T15:16:54Z</dc:date>

            13. <dc:date>2021-08-24T15:16:54Z</dc:date>

            14. <dc:date>2017-12-01</dc:date>

            15. <dc:type>research article</dc:type>

            16. <dc:identifier>Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</dc:identifier>

            17. <dc:identifier>1664-0640</dc:identifier>

            18. <dc:identifier>http://hdl.handle.net/20.500.13003/9541</dc:identifier>

            19. <dc:identifier>10.3389/fpsyt.2017.00258</dc:identifier>

            20. <dc:identifier>29326609</dc:identifier>

            21. <dc:identifier>L619582782</dc:identifier>

            22. <dc:identifier>2-s2.0-85037623572</dc:identifier>

            23. <dc:identifier>000416792100001</dc:identifier>

            24. <dc:language>eng</dc:language>

            25. <dc:relation>https://dx.doi.org/10.3389/fpsyt.2017.00258</dc:relation>

            26. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>

            27. <dc:rights>open access</dc:rights>

            28. <dc:rights>Attribution 4.0 International</dc:rights>

            29. <dc:publisher>Frontiers Media Sa</dc:publisher>

            </oai_dc:dc>

          </d:Statement>

        </d:Descriptor>

      3. <d:Component id="20.500.13003_9541_1">

        1. <d:Resource mimeType="application/pdf" ref="https://docusalut.com/bitstream/20.500.13003/9541/1/000416792100001.pdf" />

        </d:Component>

      </d:Item>

    </d:DIDL>

dim

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">

    1. <dim:field authority="511bebfc-2967-4f19-9a29-63cc0c24fb47" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Keller, Benjamin</dim:field>

    2. <dim:field authority="3abb2060-1e55-4704-ad5a-106519f6e9bb" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Mestre-Pinto, Joan-Ignasi</dim:field>

    3. <dim:field authority="5b45b765-bad0-4c01-a119-0613097dedca" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Alvaro-Bartolome, Maria</dim:field>

    4. <dim:field authority="c202da4e-0330-4196-9ab5-57dd919c3cb5" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Martinez-Sanvisens, Diana</dim:field>

    5. <dim:field authority="01e8ae87-af2a-4e39-839e-041241f781e6" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Farre, Magi</dim:field>

    6. <dim:field authority="843" confidence="500" element="contributor" mdschema="dc" orcid_id="0000-0002-9177-3775" qualifier="author">García-Fuster, M Julia</dim:field>

    7. <dim:field authority="d76c4632-d58e-414f-bbfa-009d810fbf23" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Garcia-Sevilla, Jesus A.</dim:field>

    8. <dim:field authority="e2a4b3f4-5ad9-4c74-8d44-b176eeef1ca2" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Torrens, Marta</dim:field>

    9. <dim:field authority="8bf8a51a-4542-4922-bc38-1f716fe8b9c5" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">NEURODEP Grp</dim:field>

    10. <dim:field element="date" mdschema="dc" qualifier="accessioned">2021-08-24T15:16:54Z</dim:field>

    11. <dim:field element="date" mdschema="dc" qualifier="available">2021-08-24T15:16:54Z</dim:field>

    12. <dim:field element="date" mdschema="dc" qualifier="issued">2017-12-01</dim:field>

    13. <dim:field element="identifier" lang="en" mdschema="dc" qualifier="citation">Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</dim:field>

    14. <dim:field element="identifier" mdschema="dc" qualifier="issn">1664-0640</dim:field>

    15. <dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/20.500.13003/9541</dim:field>

    16. <dim:field element="identifier" mdschema="dc" qualifier="doi">10.3389/fpsyt.2017.00258</dim:field>

    17. <dim:field element="identifier" mdschema="dc" qualifier="pmid">29326609</dim:field>

    18. <dim:field element="identifier" mdschema="dc" qualifier="pui">L619582782</dim:field>

    19. <dim:field element="identifier" mdschema="dc" qualifier="scopus">2-s2.0-85037623572</dim:field>

    20. <dim:field element="identifier" mdschema="dc" qualifier="wos">000416792100001</dim:field>

    21. <dim:field element="description" lang="en" mdschema="dc" qualifier="abstract">The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</dim:field>

    22. <dim:field element="description" lang="en" mdschema="dc" qualifier="fundingtext">The study was supported by grants SAF2011-29918 (JAG-S) and SAF2014-55903-R (MJG-F) from Ministerio de Economia y Competitividad (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) and by grants PS09/02121 and PI12/01838 (MT) from Instituto de Salud Carlos III (ISCIII) and FIS-FEDER, Madrid, Spain. The research was also funded by Redes Tematicas de Investigacion Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011, RD12/0028/0009, RD16/0017/0003, and RD16/0017/0010) (ISCIII and FEDER), Madrid, Spain. This work was also supported by grants 2012/011 and 2016/002 (MJG-F) from Delegacion del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain. BK was supported by a predoctoral contract from RETICS-RTA. MJG-F is a Ramon y Cajal Researcher (MINECO-UIB). JG-S is a member of the Institut d'Estudis Catalans (Barcelona, Catalonia, Spain). We are grateful to Esther Menoyo, Marta Perez, Soraya Martin, and Clara Gibert for their valuable assistance throughout the clinical part of the study.</dim:field>

    23. <dim:field element="language" lang="en" mdschema="dc" qualifier="iso">eng</dim:field>

    24. <dim:field element="publisher" lang="en" mdschema="dc">Frontiers Media Sa</dim:field>

    25. <dim:field element="rights" lang="*" mdschema="dc">Attribution 4.0 International</dim:field>

    26. <dim:field element="rights" lang="*" mdschema="dc" qualifier="uri">http://creativecommons.org/licenses/by/4.0/</dim:field>

    27. <dim:field element="rights" lang="en" mdschema="dc" qualifier="accessRights">open access</dim:field>

    28. <dim:field element="title" lang="en" mdschema="dc">A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</dim:field>

    29. <dim:field element="type" lang="en" mdschema="dc">research article</dim:field>

    30. <dim:field element="journal" lang="en" mdschema="dc" qualifier="title">Frontiers in Psychiatry</dim:field>

    31. <dim:field element="page" lang="en" mdschema="dc" qualifier="initial">258</dim:field>

    32. <dim:field element="relation" lang="en" mdschema="dc" qualifier="publisherversion">https://dx.doi.org/10.3389/fpsyt.2017.00258</dim:field>

    33. <dim:field element="subject" lang="en" mdschema="dc" qualifier="keyword">platelet biomarker</dim:field>

    34. <dim:field element="subject" lang="en" mdschema="dc" qualifier="keyword">IRAS/nischarin</dim:field>

    35. <dim:field element="subject" lang="en" mdschema="dc" qualifier="keyword">cocaine use disorder</dim:field>

    36. <dim:field element="subject" lang="en" mdschema="dc" qualifier="keyword">major depressive disorder</dim:field>

    37. <dim:field element="subject" lang="en" mdschema="dc" qualifier="keyword">cocaine-induced depression</dim:field>

    38. <dim:field element="subject" lang="en" mdschema="dc" qualifier="keyword">acute tryptophan depletion</dim:field>

    39. <dim:field element="subject" lang="en" mdschema="dc" qualifier="keyword">antidepressant drugs</dim:field>

    40. <dim:field element="volume" lang="en" mdschema="dc" qualifier="number">8</dim:field>

    </dim:dim>

etdms

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">

    1. <title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</title>

    2. <creator>Keller, Benjamin</creator>

    3. <creator>Mestre-Pinto, Joan-Ignasi</creator>

    4. <creator>Alvaro-Bartolome, Maria</creator>

    5. <creator>Martinez-Sanvisens, Diana</creator>

    6. <creator>Farre, Magi</creator>

    7. <creator>García-Fuster, M Julia</creator>

    8. <creator>Garcia-Sevilla, Jesus A.</creator>

    9. <creator>Torrens, Marta</creator>

    10. <creator>NEURODEP Grp</creator>

    11. <description>The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</description>

    12. <date>2021-08-24</date>

    13. <date>2021-08-24</date>

    14. <date>2017-12-01</date>

    15. <type>research article</type>

    16. <identifier>Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</identifier>

    17. <identifier>1664-0640</identifier>

    18. <identifier>http://hdl.handle.net/20.500.13003/9541</identifier>

    19. <identifier>10.3389/fpsyt.2017.00258</identifier>

    20. <identifier>29326609</identifier>

    21. <identifier>L619582782</identifier>

    22. <identifier>2-s2.0-85037623572</identifier>

    23. <identifier>000416792100001</identifier>

    24. <language>eng</language>

    25. <relation>https://dx.doi.org/10.3389/fpsyt.2017.00258</relation>

    26. <rights>http://creativecommons.org/licenses/by/4.0/</rights>

    27. <rights>open access</rights>

    28. <rights>Attribution 4.0 International</rights>

    29. <publisher>Frontiers Media Sa</publisher>

    </thesis>

marc

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">

    1. <leader>00925njm 22002777a 4500</leader>

    2. <datafield ind1=" " ind2=" " tag="042">

      1. <subfield code="a">dc</subfield>

      </datafield>

    3. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Keller, Benjamin</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    4. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Mestre-Pinto, Joan-Ignasi</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    5. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Alvaro-Bartolome, Maria</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    6. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Martinez-Sanvisens, Diana</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    7. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Farre, Magi</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    8. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">García-Fuster, M Julia</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    9. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Garcia-Sevilla, Jesus A.</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    10. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Torrens, Marta</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    11. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">NEURODEP Grp</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

    12. <datafield ind1=" " ind2=" " tag="260">

      1. <subfield code="c">2017-12-01</subfield>

      </datafield>

    13. <datafield ind1=" " ind2=" " tag="520">

      1. <subfield code="a">The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</subfield>

      </datafield>

    14. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</subfield>

      </datafield>

    15. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">1664-0640</subfield>

      </datafield>

    16. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">http://hdl.handle.net/20.500.13003/9541</subfield>

      </datafield>

    17. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">10.3389/fpsyt.2017.00258</subfield>

      </datafield>

    18. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">29326609</subfield>

      </datafield>

    19. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">L619582782</subfield>

      </datafield>

    20. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">2-s2.0-85037623572</subfield>

      </datafield>

    21. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">000416792100001</subfield>

      </datafield>

    22. <datafield ind1="0" ind2="0" tag="245">

      1. <subfield code="a">A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</subfield>

      </datafield>

    </record>

mets

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <mets ID=" DSpace_ITEM_20.500.13003-9541" OBJID=" hdl:20.500.13003/9541" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">

    1. <metsHdr CREATEDATE="2024-09-29T04:03:29Z">

      1. <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">

        1. <name>Docusalut</name>

        </agent>

      </metsHdr>

    2. <dmdSec ID="DMD_20.500.13003_9541">

      1. <mdWrap MDTYPE="MODS">

        1. <xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">

          1. <mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">

            1. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>Keller, Benjamin</mods:namePart>

              </mods:name>

            2. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>Mestre-Pinto, Joan-Ignasi</mods:namePart>

              </mods:name>

            3. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>Alvaro-Bartolome, Maria</mods:namePart>

              </mods:name>

            4. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>Martinez-Sanvisens, Diana</mods:namePart>

              </mods:name>

            5. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>Farre, Magi</mods:namePart>

              </mods:name>

            6. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>García-Fuster, M Julia</mods:namePart>

              </mods:name>

            7. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>Garcia-Sevilla, Jesus A.</mods:namePart>

              </mods:name>

            8. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>Torrens, Marta</mods:namePart>

              </mods:name>

            9. <mods:name>

              1. <mods:role>

                1. <mods:roleTerm type="text">author</mods:roleTerm>

                </mods:role>

              2. <mods:namePart>NEURODEP Grp</mods:namePart>

              </mods:name>

            10. <mods:extension>

              1. <mods:dateAccessioned encoding="iso8601">2021-08-24T15:16:54Z</mods:dateAccessioned>

              </mods:extension>

            11. <mods:extension>

              1. <mods:dateAvailable encoding="iso8601">2021-08-24T15:16:54Z</mods:dateAvailable>

              </mods:extension>

            12. <mods:originInfo>

              1. <mods:dateIssued encoding="iso8601">2017-12-01</mods:dateIssued>

              </mods:originInfo>

            13. <mods:identifier type="citation">Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</mods:identifier>

            14. <mods:identifier type="issn">1664-0640</mods:identifier>

            15. <mods:identifier type="uri">http://hdl.handle.net/20.500.13003/9541</mods:identifier>

            16. <mods:identifier type="doi">10.3389/fpsyt.2017.00258</mods:identifier>

            17. <mods:identifier type="pmid">29326609</mods:identifier>

            18. <mods:identifier type="pui">L619582782</mods:identifier>

            19. <mods:identifier type="scopus">2-s2.0-85037623572</mods:identifier>

            20. <mods:identifier type="wos">000416792100001</mods:identifier>

            21. <mods:abstract>The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</mods:abstract>

            22. <mods:language>

              1. <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>

              </mods:language>

            23. <mods:accessCondition type="useAndReproduction">Attribution 4.0 International</mods:accessCondition>

            24. <mods:titleInfo>

              1. <mods:title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</mods:title>

              </mods:titleInfo>

            25. <mods:genre>research article</mods:genre>

            </mods:mods>

          </xmlData>

        </mdWrap>

      </dmdSec>

    3. <amdSec ID="FO_20.500.13003_9541_1">

      1. <techMD ID="TECH_O_20.500.13003_9541_1">

        1. <mdWrap MDTYPE="PREMIS">

          1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">

            1. <premis:premis>

              1. <premis:object>

                1. <premis:objectIdentifier>

                  1. <premis:objectIdentifierType>URL</premis:objectIdentifierType>

                  2. <premis:objectIdentifierValue>https://docusalut.com/bitstream/20.500.13003/9541/1/000416792100001.pdf</premis:objectIdentifierValue>

                  </premis:objectIdentifier>

                2. <premis:objectCategory>File</premis:objectCategory>

                3. <premis:objectCharacteristics>

                  1. <premis:fixity>

                    1. <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>

                    2. <premis:messageDigest>5fccafae159cf24fd9799d8272e8bb2c</premis:messageDigest>

                    </premis:fixity>

                  2. <premis:size>853253</premis:size>

                  3. <premis:format>

                    1. <premis:formatDesignation>

                      1. <premis:formatName>application/pdf</premis:formatName>

                      </premis:formatDesignation>

                    </premis:format>

                  </premis:objectCharacteristics>

                4. <premis:originalName>000416792100001.pdf</premis:originalName>

                </premis:object>

              </premis:premis>

            </xmlData>

          </mdWrap>

        </techMD>

      </amdSec>

    4. <amdSec ID="FT_20.500.13003_9541_3">

      1. <techMD ID="TECH_T_20.500.13003_9541_3">

        1. <mdWrap MDTYPE="PREMIS">

          1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">

            1. <premis:premis>

              1. <premis:object>

                1. <premis:objectIdentifier>

                  1. <premis:objectIdentifierType>URL</premis:objectIdentifierType>

                  2. <premis:objectIdentifierValue>https://docusalut.com/bitstream/20.500.13003/9541/3/000416792100001.pdf.txt</premis:objectIdentifierValue>

                  </premis:objectIdentifier>

                2. <premis:objectCategory>File</premis:objectCategory>

                3. <premis:objectCharacteristics>

                  1. <premis:fixity>

                    1. <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>

                    2. <premis:messageDigest>2e06fdfd89db144aeaba35ffbdc71468</premis:messageDigest>

                    </premis:fixity>

                  2. <premis:size>47645</premis:size>

                  3. <premis:format>

                    1. <premis:formatDesignation>

                      1. <premis:formatName>text/plain</premis:formatName>

                      </premis:formatDesignation>

                    </premis:format>

                  </premis:objectCharacteristics>

                4. <premis:originalName>000416792100001.pdf.txt</premis:originalName>

                </premis:object>

              </premis:premis>

            </xmlData>

          </mdWrap>

        </techMD>

      </amdSec>

    5. <fileSec>

      1. <fileGrp USE="ORIGINAL">

        1. <file ADMID="FO_20.500.13003_9541_1" CHECKSUM="5fccafae159cf24fd9799d8272e8bb2c" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_20.500.13003_9541_1" ID="BITSTREAM_ORIGINAL_20.500.13003_9541_1" MIMETYPE="application/pdf" SEQ="1" SIZE="853253">

          1. <FLocat LOCTYPE="URL" href="https://docusalut.com/bitstream/20.500.13003/9541/1/000416792100001.pdf" type="simple" />

          </file>

        </fileGrp>

      2. <fileGrp USE="TEXT">

        1. <file ADMID="FT_20.500.13003_9541_3" CHECKSUM="2e06fdfd89db144aeaba35ffbdc71468" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_20.500.13003_9541_3" ID="BITSTREAM_TEXT_20.500.13003_9541_3" MIMETYPE="text/plain" SEQ="3" SIZE="47645">

          1. <FLocat LOCTYPE="URL" href="https://docusalut.com/bitstream/20.500.13003/9541/3/000416792100001.pdf.txt" type="simple" />

          </file>

        </fileGrp>

      </fileSec>

    6. <structMap LABEL="DSpace Object" TYPE="LOGICAL">

      1. <div ADMID="DMD_20.500.13003_9541" TYPE="DSpace Object Contents">

        1. <div TYPE="DSpace BITSTREAM">

          1. <fptr FILEID="BITSTREAM_ORIGINAL_20.500.13003_9541_1" />

          </div>

        </div>

      </structMap>

    </mets>

mods

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">

    1. <mods:name>

      1. <mods:namePart>Keller, Benjamin</mods:namePart>

      </mods:name>

    2. <mods:name>

      1. <mods:namePart>Mestre-Pinto, Joan-Ignasi</mods:namePart>

      </mods:name>

    3. <mods:name>

      1. <mods:namePart>Alvaro-Bartolome, Maria</mods:namePart>

      </mods:name>

    4. <mods:name>

      1. <mods:namePart>Martinez-Sanvisens, Diana</mods:namePart>

      </mods:name>

    5. <mods:name>

      1. <mods:namePart>Farre, Magi</mods:namePart>

      </mods:name>

    6. <mods:name>

      1. <mods:namePart>García-Fuster, M Julia</mods:namePart>

      </mods:name>

    7. <mods:name>

      1. <mods:namePart>Garcia-Sevilla, Jesus A.</mods:namePart>

      </mods:name>

    8. <mods:name>

      1. <mods:namePart>Torrens, Marta</mods:namePart>

      </mods:name>

    9. <mods:name>

      1. <mods:namePart>NEURODEP Grp</mods:namePart>

      </mods:name>

    10. <mods:extension>

      1. <mods:dateAvailable encoding="iso8601">2021-08-24T15:16:54Z</mods:dateAvailable>

      </mods:extension>

    11. <mods:extension>

      1. <mods:dateAccessioned encoding="iso8601">2021-08-24T15:16:54Z</mods:dateAccessioned>

      </mods:extension>

    12. <mods:originInfo>

      1. <mods:dateIssued encoding="iso8601">2017-12-01</mods:dateIssued>

      </mods:originInfo>

    13. <mods:identifier type="citation">Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</mods:identifier>

    14. <mods:identifier type="issn">1664-0640</mods:identifier>

    15. <mods:identifier type="uri">http://hdl.handle.net/20.500.13003/9541</mods:identifier>

    16. <mods:identifier type="doi">10.3389/fpsyt.2017.00258</mods:identifier>

    17. <mods:identifier type="pmid">29326609</mods:identifier>

    18. <mods:identifier type="pui">L619582782</mods:identifier>

    19. <mods:identifier type="scopus">2-s2.0-85037623572</mods:identifier>

    20. <mods:identifier type="wos">000416792100001</mods:identifier>

    21. <mods:abstract>The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</mods:abstract>

    22. <mods:language>

      1. <mods:languageTerm>eng</mods:languageTerm>

      </mods:language>

    23. <mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>

    24. <mods:accessCondition type="useAndReproduction">open access</mods:accessCondition>

    25. <mods:accessCondition type="useAndReproduction">Attribution 4.0 International</mods:accessCondition>

    26. <mods:titleInfo>

      1. <mods:title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</mods:title>

      </mods:titleInfo>

    27. <mods:genre>research article</mods:genre>

    </mods:mods>

ore

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">

    1. <atom:id>http://hdl.handle.net/20.500.13003/9541/ore.xml</atom:id>

    2. <atom:link href="http://hdl.handle.net/20.500.13003/9541" rel="alternate" />
    3. <atom:link href="http://hdl.handle.net/20.500.13003/9541/ore.xml" rel="http://www.openarchives.org/ore/terms/describes" />
    4. <atom:link href="http://hdl.handle.net/20.500.13003/9541/ore.xml#atom" rel="self" type="application/atom+xml" />

    5. <atom:published>2021-08-24T15:16:54Z</atom:published>

    6. <atom:updated>2021-08-24T15:16:54Z</atom:updated>

    7. <atom:source>

      1. <atom:generator>Docusalut</atom:generator>

      </atom:source>

    8. <atom:title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</atom:title>

    9. <atom:author>

      1. <atom:name>Keller, Benjamin</atom:name>

      </atom:author>

    10. <atom:author>

      1. <atom:name>Mestre-Pinto, Joan-Ignasi</atom:name>

      </atom:author>

    11. <atom:author>

      1. <atom:name>Alvaro-Bartolome, Maria</atom:name>

      </atom:author>

    12. <atom:author>

      1. <atom:name>Martinez-Sanvisens, Diana</atom:name>

      </atom:author>

    13. <atom:author>

      1. <atom:name>Farre, Magi</atom:name>

      </atom:author>

    14. <atom:author>

      1. <atom:name>García-Fuster, M Julia</atom:name>

      </atom:author>

    15. <atom:author>

      1. <atom:name>Garcia-Sevilla, Jesus A.</atom:name>

      </atom:author>

    16. <atom:author>

      1. <atom:name>Torrens, Marta</atom:name>

      </atom:author>

    17. <atom:author>

      1. <atom:name>NEURODEP Grp</atom:name>

      </atom:author>

    18. <atom:category label="Aggregation" scheme="http://www.openarchives.org/ore/terms/" term="http://www.openarchives.org/ore/terms/Aggregation" />
    19. <atom:category scheme="http://www.openarchives.org/ore/atom/modified" term="2021-08-24T15:16:54Z" />
    20. <atom:category label="DSpace Item" scheme="http://www.dspace.org/objectModel/" term="DSpaceItem" />
    21. <atom:link href="https://docusalut.com/bitstream/20.500.13003/9541/1/000416792100001.pdf" length="853253" rel="http://www.openarchives.org/ore/terms/aggregates" title="000416792100001.pdf" type="application/pdf" />

    22. <oreatom:triples>

      1. <rdf:Description about="http://hdl.handle.net/20.500.13003/9541/ore.xml#atom">

        1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceItem" />

        2. <dcterms:modified>2021-08-24T15:16:54Z</dcterms:modified>

        </rdf:Description>

      2. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/9541/1/000416792100001.pdf">

        1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

        2. <dcterms:description>ORIGINAL</dcterms:description>

        </rdf:Description>

      3. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/9541/2/license_rdf">

        1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

        2. <dcterms:description>CC-LICENSE</dcterms:description>

        </rdf:Description>

      4. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/9541/3/000416792100001.pdf.txt">

        1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

        2. <dcterms:description>TEXT</dcterms:description>

        </rdf:Description>

      5. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/9541/4/000416792100001.pdf.jpg">

        1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

        2. <dcterms:description>THUMBNAIL</dcterms:description>

        </rdf:Description>

      </oreatom:triples>

    </atom:entry>

qdc

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">

    1. <dc:title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</dc:title>

    2. <dc:creator>Keller, Benjamin</dc:creator>

    3. <dc:creator>Mestre-Pinto, Joan-Ignasi</dc:creator>

    4. <dc:creator>Alvaro-Bartolome, Maria</dc:creator>

    5. <dc:creator>Martinez-Sanvisens, Diana</dc:creator>

    6. <dc:creator>Farre, Magi</dc:creator>

    7. <dc:creator>García-Fuster, M Julia</dc:creator>

    8. <dc:creator>Garcia-Sevilla, Jesus A.</dc:creator>

    9. <dc:creator>Torrens, Marta</dc:creator>

    10. <dc:creator>NEURODEP Grp</dc:creator>

    11. <dcterms:abstract>The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</dcterms:abstract>

    12. <dcterms:dateAccepted>2021-08-24T15:16:54Z</dcterms:dateAccepted>

    13. <dcterms:available>2021-08-24T15:16:54Z</dcterms:available>

    14. <dcterms:created>2021-08-24T15:16:54Z</dcterms:created>

    15. <dcterms:issued>2017-12-01</dcterms:issued>

    16. <dc:type>research article</dc:type>

    17. <dc:identifier>Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</dc:identifier>

    18. <dc:identifier>1664-0640</dc:identifier>

    19. <dc:identifier>http://hdl.handle.net/20.500.13003/9541</dc:identifier>

    20. <dc:identifier>10.3389/fpsyt.2017.00258</dc:identifier>

    21. <dc:identifier>29326609</dc:identifier>

    22. <dc:identifier>L619582782</dc:identifier>

    23. <dc:identifier>2-s2.0-85037623572</dc:identifier>

    24. <dc:identifier>000416792100001</dc:identifier>

    25. <dc:language>eng</dc:language>

    26. <dc:relation>https://dx.doi.org/10.3389/fpsyt.2017.00258</dc:relation>

    27. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>

    28. <dc:rights>open access</dc:rights>

    29. <dc:rights>Attribution 4.0 International</dc:rights>

    30. <dc:publisher>Frontiers Media Sa</dc:publisher>

    </qdc:qualifieddc>

rdf

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">

    1. <ow:Publication about="oai:docusalut.com:20.500.13003/9541">

      1. <dc:title>A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</dc:title>

      2. <dc:creator>Keller, Benjamin</dc:creator>

      3. <dc:creator>Mestre-Pinto, Joan-Ignasi</dc:creator>

      4. <dc:creator>Alvaro-Bartolome, Maria</dc:creator>

      5. <dc:creator>Martinez-Sanvisens, Diana</dc:creator>

      6. <dc:creator>Farre, Magi</dc:creator>

      7. <dc:creator>García-Fuster, M Julia</dc:creator>

      8. <dc:creator>Garcia-Sevilla, Jesus A.</dc:creator>

      9. <dc:creator>Torrens, Marta</dc:creator>

      10. <dc:creator>NEURODEP Grp</dc:creator>

      11. <dc:description>The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</dc:description>

      12. <dc:date>2021-08-24T15:16:54Z</dc:date>

      13. <dc:date>2021-08-24T15:16:54Z</dc:date>

      14. <dc:date>2017-12-01</dc:date>

      15. <dc:type>research article</dc:type>

      16. <dc:identifier>Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</dc:identifier>

      17. <dc:identifier>1664-0640</dc:identifier>

      18. <dc:identifier>http://hdl.handle.net/20.500.13003/9541</dc:identifier>

      19. <dc:identifier>10.3389/fpsyt.2017.00258</dc:identifier>

      20. <dc:identifier>29326609</dc:identifier>

      21. <dc:identifier>L619582782</dc:identifier>

      22. <dc:identifier>2-s2.0-85037623572</dc:identifier>

      23. <dc:identifier>000416792100001</dc:identifier>

      24. <dc:language>eng</dc:language>

      25. <dc:relation>https://dx.doi.org/10.3389/fpsyt.2017.00258</dc:relation>

      26. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>

      27. <dc:rights>open access</dc:rights>

      28. <dc:rights>Attribution 4.0 International</dc:rights>

      29. <dc:publisher>Frontiers Media Sa</dc:publisher>

      </ow:Publication>

    </rdf:RDF>

xoai

Deskargatu XML

    <?xml version="1.0" encoding="UTF-8" ?>

  1. <metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">

    1. <element name="dc">

      1. <element name="contributor">

        1. <element name="author">

          1. <element name="none">

            1. <field name="value">Keller, Benjamin</field>

            2. <field name="authority">511bebfc-2967-4f19-9a29-63cc0c24fb47</field>

            3. <field name="confidence">500</field>

            4. <field name="orcid_id" />

            5. <field name="value">Mestre-Pinto, Joan-Ignasi</field>

            6. <field name="authority">3abb2060-1e55-4704-ad5a-106519f6e9bb</field>

            7. <field name="confidence">500</field>

            8. <field name="orcid_id" />

            9. <field name="value">Alvaro-Bartolome, Maria</field>

            10. <field name="authority">5b45b765-bad0-4c01-a119-0613097dedca</field>

            11. <field name="confidence">500</field>

            12. <field name="orcid_id" />

            13. <field name="value">Martinez-Sanvisens, Diana</field>

            14. <field name="authority">c202da4e-0330-4196-9ab5-57dd919c3cb5</field>

            15. <field name="confidence">500</field>

            16. <field name="orcid_id" />

            17. <field name="value">Farre, Magi</field>

            18. <field name="authority">01e8ae87-af2a-4e39-839e-041241f781e6</field>

            19. <field name="confidence">500</field>

            20. <field name="orcid_id" />

            21. <field name="value">García-Fuster, M Julia</field>

            22. <field name="authority">843</field>

            23. <field name="confidence">500</field>

            24. <field name="orcid_id">0000-0002-9177-3775</field>

            25. <field name="value">Garcia-Sevilla, Jesus A.</field>

            26. <field name="authority">d76c4632-d58e-414f-bbfa-009d810fbf23</field>

            27. <field name="confidence">500</field>

            28. <field name="orcid_id" />

            29. <field name="value">Torrens, Marta</field>

            30. <field name="authority">e2a4b3f4-5ad9-4c74-8d44-b176eeef1ca2</field>

            31. <field name="confidence">500</field>

            32. <field name="orcid_id" />

            33. <field name="value">NEURODEP Grp</field>

            34. <field name="authority">8bf8a51a-4542-4922-bc38-1f716fe8b9c5</field>

            35. <field name="confidence">500</field>

            36. <field name="orcid_id" />

            </element>

          </element>

        </element>

      2. <element name="date">

        1. <element name="accessioned">

          1. <element name="none">

            1. <field name="value">2021-08-24T15:16:54Z</field>

            </element>

          </element>

        2. <element name="available">

          1. <element name="none">

            1. <field name="value">2021-08-24T15:16:54Z</field>

            </element>

          </element>

        3. <element name="issued">

          1. <element name="none">

            1. <field name="value">2017-12-01</field>

            </element>

          </element>

        4. <element name="embargoEndDate">

          1. <element name="none" />

          </element>

        </element>

      3. <element name="identifier">

        1. <element name="citation">

          1. <element name="en">

            1. <field name="value">Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.</field>

            </element>

          </element>

        2. <element name="issn">

          1. <element name="none">

            1. <field name="value">1664-0640</field>

            </element>

          </element>

        3. <element name="uri">

          1. <element name="none">

            1. <field name="value">http://hdl.handle.net/20.500.13003/9541</field>

            </element>

          </element>

        4. <element name="doi">

          1. <element name="none">

            1. <field name="value">10.3389/fpsyt.2017.00258</field>

            </element>

          </element>

        5. <element name="pmid">

          1. <element name="none">

            1. <field name="value">29326609</field>

            </element>

          </element>

        6. <element name="pui">

          1. <element name="none">

            1. <field name="value">L619582782</field>

            </element>

          </element>

        7. <element name="scopus">

          1. <element name="none">

            1. <field name="value">2-s2.0-85037623572</field>

            </element>

          </element>

        8. <element name="wos">

          1. <element name="none">

            1. <field name="value">000416792100001</field>

            </element>

          </element>

        </element>

      4. <element name="description">

        1. <element name="abstract">

          1. <element name="en">

            1. <field name="value">The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.</field>

            </element>

          </element>

        2. <element name="fundingtext">

          1. <element name="en">

            1. <field name="value">The study was supported by grants SAF2011-29918 (JAG-S) and SAF2014-55903-R (MJG-F) from Ministerio de Economia y Competitividad (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) and by grants PS09/02121 and PI12/01838 (MT) from Instituto de Salud Carlos III (ISCIII) and FIS-FEDER, Madrid, Spain. The research was also funded by Redes Tematicas de Investigacion Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011, RD12/0028/0009, RD16/0017/0003, and RD16/0017/0010) (ISCIII and FEDER), Madrid, Spain. This work was also supported by grants 2012/011 and 2016/002 (MJG-F) from Delegacion del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain. BK was supported by a predoctoral contract from RETICS-RTA. MJG-F is a Ramon y Cajal Researcher (MINECO-UIB). JG-S is a member of the Institut d'Estudis Catalans (Barcelona, Catalonia, Spain). We are grateful to Esther Menoyo, Marta Perez, Soraya Martin, and Clara Gibert for their valuable assistance throughout the clinical part of the study.</field>

            </element>

          </element>

        </element>

      5. <element name="language">

        1. <element name="iso">

          1. <element name="en">

            1. <field name="value">eng</field>

            </element>

          </element>

        </element>

      6. <element name="publisher">

        1. <element name="en">

          1. <field name="value">Frontiers Media Sa</field>

          </element>

        </element>

      7. <element name="rights">

        1. <element name="*">

          1. <field name="value">Attribution 4.0 International</field>

          </element>

        2. <element name="uri">

          1. <element name="*">

            1. <field name="value">http://creativecommons.org/licenses/by/4.0/</field>

            </element>

          </element>

        3. <element name="accessRights">

          1. <element name="en">

            1. <field name="value">open access</field>

            </element>

          </element>

        </element>

      8. <element name="title">

        1. <element name="en">

          1. <field name="value">A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)</field>

          </element>

        </element>

      9. <element name="type">

        1. <element name="en">

          1. <field name="value">research article</field>

          </element>

        </element>

      10. <element name="journal">

        1. <element name="title">

          1. <element name="en">

            1. <field name="value">Frontiers in Psychiatry</field>

            </element>

          </element>

        </element>

      11. <element name="page">

        1. <element name="initial">

          1. <element name="en">

            1. <field name="value">258</field>

            </element>

          </element>

        </element>

      12. <element name="relation">

        1. <element name="publisherversion">

          1. <element name="en">

            1. <field name="value">https://dx.doi.org/10.3389/fpsyt.2017.00258</field>

            </element>

          </element>

        </element>

      13. <element name="subject">

        1. <element name="keyword">

          1. <element name="en">

            1. <field name="value">platelet biomarker</field>

            2. <field name="value">IRAS/nischarin</field>

            3. <field name="value">cocaine use disorder</field>

            4. <field name="value">major depressive disorder</field>

            5. <field name="value">cocaine-induced depression</field>

            6. <field name="value">acute tryptophan depletion</field>

            7. <field name="value">antidepressant drugs</field>

            </element>

          </element>

        </element>

      14. <element name="volume">

        1. <element name="number">

          1. <element name="en">

            1. <field name="value">8</field>

            </element>

          </element>

        </element>

      </element>

    2. <element name="bundles">

      1. <element name="bundle">

        1. <field name="name">ORIGINAL</field>

        2. <element name="bitstreams">

          1. <element name="bitstream">

            1. <field name="name">000416792100001.pdf</field>

            2. <field name="format">application/pdf</field>

            3. <field name="size">853253</field>

            4. <field name="url">https://docusalut.com/bitstream/20.500.13003/9541/1/000416792100001.pdf</field>

            5. <field name="checksum">5fccafae159cf24fd9799d8272e8bb2c</field>

            6. <field name="checksumAlgorithm">MD5</field>

            7. <field name="sid">1</field>

            8. <field name="drm">open access</field>

            </element>

          </element>

        </element>

      2. <element name="bundle">

        1. <field name="name">CC-LICENSE</field>

        2. <element name="bitstreams">

          1. <element name="bitstream">

            1. <field name="name">license_rdf</field>

            2. <field name="format">application/octet-stream</field>

            3. <field name="size">908</field>

            4. <field name="url">https://docusalut.com/bitstream/20.500.13003/9541/2/license_rdf</field>

            5. <field name="checksum">0175ea4a2d4caec4bbcc37e300941108</field>

            6. <field name="checksumAlgorithm">MD5</field>

            7. <field name="sid">2</field>

            8. <field name="drm">open access</field>

            </element>

          </element>

        </element>

      3. <element name="bundle">

        1. <field name="name">TEXT</field>

        2. <element name="bitstreams">

          1. <element name="bitstream">

            1. <field name="name">000416792100001.pdf.txt</field>

            2. <field name="originalName">000416792100001.pdf.txt</field>

            3. <field name="description">Extracted text</field>

            4. <field name="format">text/plain</field>

            5. <field name="size">47645</field>

            6. <field name="url">https://docusalut.com/bitstream/20.500.13003/9541/3/000416792100001.pdf.txt</field>

            7. <field name="checksum">2e06fdfd89db144aeaba35ffbdc71468</field>

            8. <field name="checksumAlgorithm">MD5</field>

            9. <field name="sid">3</field>

            10. <field name="drm">open access</field>

            </element>

          </element>

        </element>

      4. <element name="bundle">

        1. <field name="name">THUMBNAIL</field>

        2. <element name="bitstreams">

          1. <element name="bitstream">

            1. <field name="name">000416792100001.pdf.jpg</field>

            2. <field name="originalName">000416792100001.pdf.jpg</field>

            3. <field name="description">IM Thumbnail</field>

            4. <field name="format">image/jpeg</field>

            5. <field name="size">12161</field>

            6. <field name="url">https://docusalut.com/bitstream/20.500.13003/9541/4/000416792100001.pdf.jpg</field>

            7. <field name="checksum">c3bbcad7e9d5291d407e1672b6db7315</field>

            8. <field name="checksumAlgorithm">MD5</field>

            9. <field name="sid">4</field>

            10. <field name="drm">open access</field>

            </element>

          </element>

        </element>

      </element>

    3. <element name="others">

      1. <field name="handle">20.500.13003/9541</field>

      2. <field name="identifier">oai:docusalut.com:20.500.13003/9541</field>

      3. <field name="lastModifyDate">2024-04-05 12:59:10.054</field>

      4. <field name="drm">open access</field>

      </element>

    4. <element name="repository">

      1. <field name="name">Docusalut</field>

      2. <field name="mail">docusalut@bibliosalut.com</field>

      </element>

    </metadata>

Hispana

Kultura digitalera sartzeko ataria eta Europeanaren agregatzaile nazionala

Harremanetarako

Sar zaitez gure inprimakira eta lehenbailehen erantzungo dizugu

Harremanetarako

Twitter

Tweets by Hispana_roai

Facebook

HISPANA
© Ministerio de Cultura y Deporte
  • Ohar legala
  • Irisgarritasuna